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Abstract
Background: To study the ability of tepoxalin, a dual inhibitor of cyclooxygenase (COX) and
lipoxygenase (LOX) and its active metabolite to reduce the catabolic response of cartilage to
cytokine stimulation in an in vitro model of canine osteoarthritis (OA).
Grossly normal cartilage was collected post-mortem from seven dogs that had no evidence of joint
disease. Cartilage explants were cultured in media containing the recombinant canine interleukin-
1β (IL-1β) at 100 ng/ml and recombinant human oncostatin-M (OSM) at 50 ng/ml. The effects of
tepoxalin and its metabolite were studied at three concentrations (1 × 10-5, 1 × 10-6 and 1 × 10-7
M). Total glycosaminoglycan (GAG) and collagen (hydroxyproline) release from cartilage explants
were used as outcome measures of proteoglycan and collagen depletion respectively. PGE2 and
LTB4 assays were performed to study the effects of the drug on COX and LOX activity.
Results: Treatment with IL-1β and OSM significantly upregulated both collagen (p = 0.004) and
proteoglycan (p = 0.001) release from the explants. Tepoxalin at 10-5 M and 10-6 M caused a
decrease in collagen release from the explants (p = 0.047 and p = 0.075). Drug treatment showed
no effect on GAG release. PGE2 concentration in culture media at day 7 was significantly increased
by IL-1β and OSM and treatment with both tepoxalin and its metabolite showed a trend towards
dose-dependent reduction of PGE2 production. LTB4 concentrations were too low to be quantified.
Cytotoxicity assays suggested that neither tepoxalin nor its metabolite had a toxic effect on the
cartilage chondrocytes at the concentrations and used in this study.
Conclusion: This study provides evidence that tepoxalin exerts inhibition of COX and can reduce
in vitro collagen loss from canine cartilage explants at a concentration of 10-5 M. We can conclude
that, in this model, tepoxalin can partially inhibit the development of cartilage degeneration when
it is available locally to the tissue.
Background
Osteoarthritis (OA) is the most common arthropathy of
mammals and affects approximately 20% of the adult
canine population [1]. The condition is typically treated
with nonsteroidal anti-inflammatory drugs (NSAIDs),
often for many months or years.
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OA is characterised by the degeneration and loss of artic-
ular cartilage. The single cell type of cartilage is the
chondrocyte and this cell is the architect of an extracellu-
lar matrix consisting mainly of water, type II collagen and
proteoglycans [2]. The major proteoglycan of cartilage,
aggrecan, contains large numbers of glycosaminoglycan
(GAG) side-chains. Collagen provides the tensile strength
to the tissue whereas aggrecan imbibes water thereby pro-
viding compressive stiffness [3]. In canine OA, an early
event is the loss of aggrecan through degradative enzymic
activity by aggrecanases (ADAMTS-4, -5) [4]. Aggrecan
loss renders the collagen network susceptible to degrada-
tion by the matrix metalloproteases, MMP-1 and -13
[5,6]. The overall effect of increased degradation and inap-
propriate synthesis is a gradual loss of tissue. It is thought
that the upregulation of matrix degradation and downreg-
ulation of synthesis is mediated through catabolic
cytokines such as IL-1β, IL-6 and oncostatin-M (OSM) [7-
9].
Culturing cartilage explants is a well established tool for
studying inflammatory processes and in vitro models of
cartilage degradation in several domestic species have
been developed [10,11] including species of veterinary
interest [12-14]. These models utilize a variety of catabolic
cytokines to induce cartilage degradation and depress
matrix synthesis in explants of cartilage retrieved from
normal joints. The release of these organic components
from the explants can be measured by using assays for gly-
cosaminoglycan and hydroxyproline (a direct measure of
collagen release) on the culture media.
There is clearly great interest in drugs that might retard,
stop or reverse the biological processes of OA and preserve
cartilage tissue integrity. Because NSAIDs are used rou-
tinely in the management of OA pain, often for protracted
periods of time, the effect of NSAIDs on cartilage has been
previously studied. Early studies in the 1980s demon-
strated that in a canine in vivo model of OA, aspirin had
negative effects on cartilage metabolism [15]. Highlight-
ing the increase in clinical use of agents that show
enhanced COX-2 selectivity more recent in vitro studies
have demonstrated some limited positive effects for car-
profen (Rimadyl) on the synthesis of aggrecan [14]. To
date, effects on the degradative pathways have received lit-
tle attention.
Recent work on dual COX-LOX inhibitors has highlighted
possible desirable effects on inhibiting both cyclooxygen-
ase and lipoxygenase pathways on cartilage metabolism.
As well as the expected inhibition of PGE2 and LTB4 pro-
duction, studies of licofelone (ML-3000) in an experi-
mental canine model (Pond-Nuki) of OA demonstrated
an ability to decrease progression of OA compared to
untreated controls [16]. In particular, this study suggested
a decrease in MMP-1 and IL-1β in cartilage in treated
groups. Although, a direct comparison was not per-
formed, the investigators suggested that the effect of
licofelone was more pronounced than the effects the same
investigators had reported with carprofen in a similar
model [17]. Furthermore, licofelone has been shown to
reduce gene expression of MMP-13, ADAMTS-4 and
cathepsin K with corresponding reductions in appearance
of protein [18].
Tepoxalin is a dual COX/LOX inhibitor. Previous work
has shown that tepoxalin can reduce the production of IL-
1 by human synovial tissue explants in organ culture [19],
suggesting that tepoxalin may have beneficial effects on
cartilage in OA, limiting both the production of endog-
enous IL-1 and consequent MMP-mediated tissue degra-
dation.
The aim of this study was to use an in vitro model of
canine OA to investigate the hypothesis that tepoxalin, a
dual COX/LOX inhibitor, is able to reduce the catabolic
response of cartilage to cytokine stimulation. OSM and IL-
1β have previously been described as a potent combina-
tion in promoting cartilage release in cartilage [7,20].
Total GAG and collagen (hydroxyproline) release in to the
tissue culture media were used as outcome measures of
proteoglycan and collagen depletion respectively. We
demonstrate that tepoxalin, at 10-5 M and 10-6 M, caused
a decrease in collagen release from canine articular carti-
lage explants in vitro.
Methods
Tissue collection and explant culture
Grossly normal articular load-bearing cartilage was har-
vested from the femoral condyles and trochlear groove of
distal femurs of seven dogs euthanatized for reasons unre-
lated to musculoskeletal disorders and for reasons unre-
lated to this study and which had no evidence of gross
joint disease on post-mortem examination. Full,
informed consent from owners was obtained prior to tis-
sue harvest. Using aseptic technique throughout, the car-
tilage explants were washed three times in serum-free
Dulbecco's Modified Eagle's Medium (DMEM) supple-
mented with 300 units/ml penicillin and 100 units/ml
streptomycin (all from Cambrex, Wokingham, UK).
Cartilage degradation assay
Individual cartilage explants (approximately 0.75 cm2)
were placed in 24-well tissue culture plates containing 1
ml of serum-free DMEM supplemented with 100 units/ml
penicillin and 100 units/ml streptomycin as described in
other studies [21]. Explants in triplicate wells were
exposed to treatments with each horse treated as a sepa-
rate experiment. Recombinant canine (rc) IL-1β  (R&D
Systems, Abingdon, UK) and recombinant human (rh)BMC Veterinary Research 2009, 5:25 http://www.biomedcentral.com/1746-6148/5/25
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OSM (Peprotech, London, UK) were added at final con-
centrations of 100 ng/ml and 50 ng/ml, respectively, to all
explant cultures, with the exception of a triplicate negative
control group. The effects of tepoxalin and its metabolite
were studied at three concentrations (1 × 10-5, 1 × 10-6 and
1 × 10-7 M), which have previously been reported to be
representative of doses expected to be reached in the
human joint during therapy [22]. Additionally, pharma-
cokinetic data from the technical monograph for the
licensed form of tepoxalin (Zubrin, Intervet-Schering
Plough Animal Health) and its active metabolite indicate
that following the recommended loading dose of 20 mg/
kg followed by six days of 10. mg/kg plasma Cmax values
range from 1.48 × 10-6 M and 2.8 × 10-6 M suggesting that
our selected concentrations spanned the concentrations
likely to be achieved in the synovial joint. Cultures were
maintained for 28 days (at 37°C in a humidified 5%
CO2:95% air mixture) and the medium containing stim-
uli and drug were harvested and replenished every 7 days
throughout this period. Harvested media was stored at -
20°C prior to GAG and hydroxyproline analysis. Media
samples collected at day 7 were assayed for GAG release
while collagen degradation and release was measured in
media collected at days 7, 14, 21 and 28, all were stored at
-20°C prior to assay. To determine the total GAG and col-
lagen content of the explants, the remaining cartilage was
digested overnight in 10 units/ml papain (Sigma, UK), 0.1
M sodium acetate, 2.4 mM ethylenediaminetetraecetic
acid, 5 mM L-cysteine, pH 5.8 at 60°C.
Proteoglycan degradation
Media collected on day 7 were assayed for total GAG using
the a modification of the dimethylmethylene blue direct
dye binding assay [23]. GAG concentration was measured
via absorbance at 570 nm with 1,9-dimethylmethylene
blue (DMMB) using shark chondroitin sulphate (both
Sigma) to establish a standard curve over 5 to 40 μg/ml.
Absorbance values were measured using a Dynex revela-
tion 4.04 plate reader (DYNEX technologies) Values were
quoted as mg per g wet weight of tissue.
Collagen degradation
Culture media collected on days 7, 14, 21 and 28 and
papain digested tissue were hydrolysed overnight in 6 M
HCl at 110°C and subsequently freeze-dried. The
lyophilised material was redissolved in distilled water. 40
μl aliquots of redissolved samples or hydroxyproline
standards were assayed for total collagen using the
hydroxyproline assay as described previously [21].
Absorbance at 560 nm was measured using a Multiskan
EX reader (Thermo Scientific) and accumulative amounts
of hydroxyproline released over the 28 day culture period
into the medium as collagen were calculated as % of total
hydroxyproline in the explant.
Effect of tepoxalin on COX and LOX activity in cartilage
PGE2 and LTB4 concentrations in media (harvested on day
seven) were determined using commercially available
competitive ELISA kits (R&D systems), in accordance with
the manufacturer's instructions. Plates were read using a
Dynex revelation 4.04 plate reader, with absorbance set at
450 nm and corrected by measurements taken at 570 nm.
Best fit polynomial standard curves were developed for
each plate, and these equations were used to calculate
PGE2 or LTB4 concentrations for samples from each plate.
Toxicity assays
Grossly normal cartilage was harvested as above from two
dogs, with no evidence of joint disease. Explants were cul-
tured in triplicate in 96 well plate format for 24 and 48
hours in 100 μl serum-free media containing catabolic
cytokines (100 ng/ml IL-1β and 50 ng/ml OSM) and
either tepoxalin or its metabolite at concentrations of 1 ×
10-5 M, 1 × 10-6 M or 1 × 10-7 M. Explants were also cul-
tured, in triplicate, in negative (serum free media) and
positive control (serum free media containing IL-1β and
OSM) conditions. Media was harvested at both time
points and replaced with 100 μl serum-free DMEM and 10
μl lysis buffer (supplied with kit). Explants were then fro-
zen at -70°C for a minimum of 1 h prior to analysis. Anal-
ysis of both the harvested media and the cell lysates
liberated from explants were performed using the com-
mercially available Cytox96® non-radioactive cytotoxicity
assay kit (Promega, Southampton, UK) which detects
release of the enzyme, lactate dehydrogenase, indicating a
loss of cellular integrity.
Statistical analysis
Statistical analysis compared triple replicates of tepoxalin-
or metabolite-treated explants from seven individuals to
the same number of explants treated with cytokines alone
using linear mixed effects regression models, with the
donor being the random effect. Where appropriate, the
data was transformed to achieve a normal distribution
Results
Proteoglycan release from cytokine-treated cultured 
explants
Our previous studies of cultured cartilage explants have
shown that treatment with IL-1β and OSM significantly
increase proteoglycan degradation after seven days in cul-
ture compared with controls [13]. We used this informa-
tion to determine whether the addition of tepoxalin or it
metabolite would influence the amount of proteoglycan
released into the culture media. As shown previously,
treatment with IL-1β and OSM significantly upregulated
proteoglycan degradation by a mean value of 2.7-fold (n
= 7, p = 0.001). Treatment with tepoxalin or its metabolite
over the concentrations ranges used showed no significantBMC Veterinary Research 2009, 5:25 http://www.biomedcentral.com/1746-6148/5/25
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effect on the amount of proteoglycan released from the
explants (figure 1).
Collagen release from cytokine-treated cultured explants
In agreement with previous studies, a significant 6.4-fold
(mean) increase (p = 0.004) in collagen release (over 28
days) from explants cultured with IL-1β and OSM was
observed in all dogs with the exception of one donor that
was included in the data shown. Treatment with tepoxalin
at a concentration of 1 × 10-5 M caused a significant 1.39-
fold mean decrease in collagen release (p = 0.047), while
treatment with tepoxalin at 10-6  M showed a trend
towards significantly reducing collagen release from the
explant (a 1.35-fold decrease, p = 0.075) (figure 2). Treat-
ments with tepoxalin at 1 × 10-7 M and its active metabo-
lite caused a minor reduction in collagen released from
the explants, however, the effect of these treatments were
not statistically significant.
PGE2 concentrations in media
Treatment with OSM and IL-1β caused a significant 98-
fold increase of PGE2 release into the media from explants
in the positive control group when compared to media
from the negative controls. Treatment with tepoxalin at 1
× 10-5 M, 1 × 10-6 M or 1 × 10-7 M concentrations reduced
this level by 4.80-fold, 1.66-fold and 1.55-fold, respec-
tively (figure 3). Treatment with the active metabolite at
concentrations of 1 × 10-5 M, 1 × 10-6 M or 1 × 10-7 M also
caused a large reduction in the levels of PGE2 released
from the explants (8.26-fold, 9.22-fold and 2.25-fold,
respectively). Concentrations of LTB4 in media harvested
from explants on day seven were not able to be quantified
due to the low levels present (data not shown). Monol-
ayer cultures that were performed for 24 h in an attempt
to obtain quantifiable levels of LTB4 also failed to achieve
levels of LTB4, which could be quantified using available
assays (data not shown).
Cytotoxicity of drug treatment
Release of the enzyme lactate dehydrogenase (LDH) from
cells or explants into the tissue culture medium is a
marker for disruption of the cell membrane integrity and
an index of cell death. No significant increase in the LDH
activity over that measured in explants treated with
cytokines alone was observed in the explant culture
medium after 24 h treatment nor 48 h treatment with
tepoxalin or its metabolite (figure 4).
Effect of tepoxalin and its metabolite on proteoglycan degradation expressed as an average value from four dogs after 7 days of  culture Figure 1
Effect of tepoxalin and its metabolite on proteoglycan degradation expressed as an average value from four 
dogs after 7 days of culture. Explants were cultured in serum free media containing IL-1β (100 ng/ml) and OSM (50 ng/ml) 
along with tepoxalin (T) or its metabolite (M) at ×10-5, ×10-6 or ×10-7 M concentrations. Proteoglycan release (GAG in 
medium) is expressed as milligrams of GAG per gram of wet weight of cartilage. Data represents means + standard error, n = 
7. P values correspond to comparisons to the positive control.
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Discussion
This study provides evidence that tepoxalin exerts an
inhibitory effect on cytokine-induced COX activity and
can also, to a certain extent, reduce in vitro collagen loss
from canine cartilage explants at a concentration of 10-5
M. An increased understanding of the pathophysiology of
OA has prompted the development of many drugs and
compounds for the treatment of the disease. A number of
other drugs with activity directed at inhibiting COX
enzymes, such as the NSAIDs, have been in use for many
years. Although they very effectively reduce the symptoms
of the disease (Husni et al., 2001), they have shown lim-
ited ability to decrease the in vivo progression of experi-
mental OA [17] and may even have adverse direct effects
on cartilage [15,24]. More recently, several studies have
reported findings indicating that dual COX/LOX inhibi-
tors have enhanced efficacy in delaying progression of the
disease. One study [16] reported that ML-3000, a dual
COX/LOX inhibitor was more effective in reducing devel-
opment of OA in a canine model than other NSAIDs, such
as tiaprofenic acid and carprofen. It was suggested that the
ability of ML-3000 to achieve more effective inhibition of
OA progression was due to its ability to inhibit LTB4 in
addition to PGE2.
In order to simulate the progressive degradation of carti-
lage observed in OA, in vitro models using explants of car-
tilage harvested from the articular surfaces of joints have
been developed. In such models, the cartilage is in isola-
tion and the direct effects of biological stimuli or pharma-
cological agents applied to the cartilage can be
investigated. Stimulation of chondrocytes with IL-1β
results in the inhibition of synthesis of ECM macromole-
cules such as aggrecan and collagen and also, induces
excess production of matrix degrading activities such as
MMPs. In agreement with this, our findings showed that
treating explants with rcIL-1β and rhOSM promotes sig-
nificant increases in collagen and GAG release. In this
study, both tepoxalin and its active metabolite were added
to cartilage incubations in order to investigate their activ-
ities in the cartilage model. Tepoxalin was found to be
able to reduce the IL-1β- and OSM-stimulated collagen
release but it had no significant effect on GAG release.
Collagen degradation requires the combined use of IL-1
and OSM to induce degradation of a relatively small pro-
portion of the total collagen and therefore, the pathways
involved may be more amenable to inhibition in this
instance. Caution should be exercised before excluding
the possibility that its metabolite can also prevent colla-
Average collagen released from explants after 28 days of culture Figure 2
Average collagen released from explants after 28 days of culture. Explants were cultured in serum free media con-
taining IL-1β (100 ng/ml) and OSM (50 ng/ml) along with tepoxalin (T) or its metabolite (M) at ×10-5, ×10-6 or ×10-7 M concen-
trations. Values represent means + standard error, n = 7. P values correspond to comparisons to the positive control; * 
significant at p ≤ 0.05.
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gen loss in vivo, as within the joint, the cartilage is not in
isolation and the activity of both tepoxalin and the metab-
olite on the surrounding tissues may be of importance in
preventing the synthesis of inflammatory agents.
We did not observe a dose-dependent effect on collagen
release, although our concentrations of tepoxalin and its
metabolite were limited to those around the therapeutic
range. It is possible that higher concentrations may have
had a more dramatic effect but we wanted to only investi-
gate concentrations around the therapeutic range. Clearly
higher concentrations would not be possible in vivo due to
systemic toxicity and potential adverse events. A reduction
in collagen degradation is theoretically a beneficial effect
[25,26] and, even if this effect is small, because NSAIDs
may be used for many months or years, small effects can
be important in the development of a slowly-progressive
disease such as OA. However, further in vivo work would
be required to confirm the translation of this initial in vitro
finding in to an animal model or clinical disease.
The failure to observe an effect on GAG release is perhaps
surprising, although it is possible that experimental con-
ditions affected these data. Negative control tissue also
released GAG in considerable amounts and this is
expected in such experiment, However, it does limit the
sensitivity of the system to detect differences between pos-
itive and negative control and small effects might go
undetected. In addition, the ease of inducing proteogly-
can loss in vitro (both IL-1 and OSM will initiate GAG loss
whether used in isolation or combination) suggests that
the loss may be difficult to inhibit once initiated. That
said, previous studies have shown that other NSAIDs such
as the COX-2 inhibitor, celecoxib, are able to reduce the
release of resident and newly-synthesized GAG in human
osteoarthritic cartilage in vitro [27]
Our toxicity assay data indicated that neither tepoxalin,
nor its active metabolite, had observable toxic effects on
chondrocytes in explants at the sampling points of our
study. However, although one would expect toxic effects
to show in a short timeframe, the sampling points in our
study were restricted to 24 and 48 hours of culture.
Both tepoxalin and its metabolite have previously been
shown to have a dose-dependent decrease on PGE2 levels
in an in vitro synovial tissue model [28]. Willburger and
co-workers [28] reported that the acid metabolite is a pure
COX inhibitor on isolated enzymes, and showed that it
could inhibit both PG and LTC4 release. While the mech-
Effect of tepoxalin and its metabolite on PGE2 levels released into culture media of canine cartilage explants Figure 3
Effect of tepoxalin and its metabolite on PGE2 levels released into culture media of canine cartilage explants. 
Media was harvested after seven days of treatment with tepoxalin (T) or its active metabolite (M) at concentrations of ×10-5, 
×10-6 or ×10-7 M. Values are shown as the mean and SDs from a single donor. P values correspond to comparisons to the pos-
itive control; * significant at p ≤ 0.05.
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Percentage of total LDH released from explants when cultured for 24 hours and 48 hours in each drug treatment condition for  A) donor 1; B) donor 2 Figure 4
Percentage of total LDH released from explants when cultured for 24 hours and 48 hours in each drug treat-
ment condition for A) donor 1; B) donor 2. Explants were cultured in serum free media containing IL-1β (100 ng/ml) and 
OSM (50 ng/ml) along with tepoxalin (T) or its metabolite (M) at ×10-5, ×10-6 or ×10-7 M concentrations. Values represent the 
mean + SDs. There were no significant differences.
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anism of action of the metabolite remained uncertain, a
direct 5-LO or 12-LO inhibition was excluded. It was
therefore hypothesised that other mechanisms such as
inhibition of cytosolic phospholipase A2 could be a possi-
ble route for its activity.
In contrast to the metabolite, tepoxalin can inhibit multi-
ple enzymatic activities (COX, 5-LO, 12-LO) [28]. In this
current study, it was found that the metabolite was capa-
ble of reducing cytokine-induced PGE2 levels to lower lev-
els than corresponding concentrations of tepoxalin,
however, unlike tepoxalin it did not significantly reduce
collagen loss from the explants. It is therefore possible
that the reduced cytokine-stimulated collagen release
from explants treated with tepoxalin 10-5 and 10-6 M was
a consequence of its inhibition of multiple enzymes and
its effect on leukotriene biosynthesis.
Analysis of explants treated with cytokines in the presence
of 10-5 M tepoxalin, which is within the therapeutic range,
showed both reduced PGE2 levels and also decreased level
of collagen release from the cartilage explants compared
to explants treated with cytokines alone. Further studies
are required to investigate the pathways that lead to colla-
gen degradation in order to provide explanation for these
findings, however it could be hypothesised that there may
be a reduction in the synthesis of IL-1β in these explants
due to reduced activity of COX, which could in turn be
responsible for reduced levels of collagen release. How-
ever, while it is well known that PGE2  is intimately
involved in inflammation, by-products of the 5-LOX
pathway, more specifically LTB4, have also been shown to
play a direct pathogenic role in OA [29]. In the OA syno-
vial membrane, both in vitro and in vivo, LTB4 up-regulates
the synthesis of the proinflammatory cytokines IL-1 and
tumor necrosis factorα (TNFα) [30] as well as matrix met-
alloproteases (MMPs).
Our findings show that both tepoxalin, and its metabo-
lite, had a similar trend towards producing a dose-
dependent reduction in PGE2  levels. Unfortunately,
despite using a variety of in vitro models, we were unable
to obtain quantifiable levels of LTB4. However, LTB4 (and
LTC4) have been reported to originate almost exclusively
from the synovial tissue, rather than articular cartilage
(Wittenberg et al., 1993), which may provide an explana-
tion for the low levels of LTB4 observed in this study. Con-
sequently in this study we were unable to quantify LTB4
due to the limited sensitivity of the assays to the very low
levels of ligand available.
Conclusion
In conclusion, this study demonstrated that tepoxalin, a
dual inhibitor of COX/LOX statistically significantly
reduced collagen loss in an in vitro experimental model of
OA. While neither tepoxalin, nor its metabolite, could
inhibit GAG loss in vitro, tepoxalin alone inhibited loss of
collagen. The mechanisms underlying this difference need
further investigation.
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